News
-
-
COMMUNIQUÉ DE PRESSE
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
-
-
-
-
COMMUNIQUÉ DE PRESSE
CureVac Announces Voting Results of Extraordinary General Meeting
-
COMMUNIQUÉ DE PRESSE
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
-
COMMUNIQUÉ DE PRESSE
CureVac Announces Pricing of Upsized Public Offering of Common Shares
-
COMMUNIQUÉ DE PRESSE
CureVac Announces Proposed Public Offering of Common Shares
-
COMMUNIQUÉ DE PRESSE
CureVac Welcomes Myriam Mendila as New Chief Development Officer